Ask Lazlo

life sciences… only

Alnylam Pharmaceuticals (ALNY)

Alnylam PharmaceuticalsCore Competency: RNAi interference

Alliances: Novartis, Roche, Takeda

News: Purchased 116 pieces of IP from Nucleonics (Dec. 8, 2008)  Looks like Alnylam is making a move to cluster and consolidate its presence in the RNAi space in terms of IP positioning.

RNAi platforms seem to be all the rage right now, so such a move seems a strong strategic advance for the Cambridge, MA company.

December 9, 2008 Posted by | Biotech, Companies | , , , , , | Leave a comment

Genentech Purchase?

The proposed deal that would involve Roche’s (RHHBY) outright purchase of Genentech (DNA) may not go through.  The rumored bid of $43.7B for the remaining 44% of Genentech that Roche does not presently own would require a $45B loan, which appears to be hung up at the moment.  

The lending squeeze is apparently the culprit, as reported by Reuters.  The deal itself makes sense, but the magnitude of the required loan is just not feasible in the present economic climate.

Nonetheless, the Genentech buyout remains on the table. Read this article over at Pharmalot for further analysis on the matter.

December 5, 2008 Posted by | Biotech, Deals, Pharma | , , , | Leave a comment

Severin Schwan: Roche Pharmaceuticals, CEO

80xName: Severin Schwan

Company: Roche Pharmaceuticals

Position: CEO

Bio (from Business Week)

Severin Schwan has been Group Chief Executive Officer of Roche Diagnostics Corporation since January 1, 2008. Dr. Schwan serves as Chief Executive Officer of Roche Holding AG. He served as Chief Executive Officer of Roche Diagnostics Corporation a Diagnostics Divisions of Roche Holding Ag, since January 1, 2006. He served as Trainee of Corporate Finance, Roche Basel from 1993 to 1995, Head Finance & Administration, Roche Brussels from 1995 to 1998, Head Finance & Informatics of Roche Grenzach and Member of the Executive Board of Roche Deutschland Holding GmbH from 1998 to 2000, Head Global Finance & Services of Roche Diagnostics from 2000 to 2004, Head Region Asia Pacific of Roche Diagnostics from 2004 to 2006. He served as a Head of Diagnostics Asia-Pacific of Roche Holding Ag from 2004 to January 1, 2006. He served as Head of Global Finance & Services for the Diagnostics Division from 2000 until 2004. Dr. Schwan holds Degree in Economics at University of Innsbruck, University of York and University of Oxford Mag. rer.soc.oec. (Innsbruck, 1991) and Law at University of Innsbruck Mag. iur. (Innsbruck, 1991) and Doctorate in Law at University of Innsbruck Research studies at University Louvain, Belgium Dr. iur. (Innsbruck, 1993).

 

WSJ Interview (Dec. 8, 2008)

November 28, 2008 Posted by | Profiles | , , | Leave a comment

All Just a Memory

Roche Pharmaceuticals (RHHBY) announced a $50M acquisition purchase of Memory Pharmaceuticals, a small-cap biotech developing CNS compounds that had an existing partnership with Roche.

Memory has developed a class of nicotinic alpha-7 agonists, which are in Phase II trials for the treatment of Alzheimer’s and schizophrenia.  The drugs treat the cognitive dysfunction of these CNS disorders through their interaction with nicotinic receptors in the brain.

November 26, 2008 Posted by | Biotech, Deals, Pharma | , , , , | Leave a comment